Technical analysis of ABVC BioPharma, Inc. (ABVC): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer.
Price Performance
| 1 month | +24.70% |
| 3 months | -20.00% |
| Year-to-date | -49.30% |
| 1 year | -62.24% |
| 3 years | +1.89% |
| 5 years | -96.22% |
52-Week Range
| 52-week High | $3.40 |
| 52-week Low | $0.71 |
| Avg Volume (90d) | 135K |
Technical Indicators
| SMA 50 | $1.05 |
| SMA 200 | $1.45 |
| Beta | 0.38 |
| 30-day Volatility (annualised) | 96.6% |
| Price vs SMA 50 | +2.8% |
| Price vs SMA 200 | -25.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.80 | |
| 2025-11 | $2.71 | -3.2% |
| 2025-12 | $2.13 | -21.4% |
| 2026-01 | $2.02 | -5.2% |
| 2026-02 | $1.31 | -35.1% |
| 2026-03 | $0.97 | -25.9% |
| 2026-04 | $1.03 | +6.2% |
| 2026-05 | $1.41 | +36.9% |
| 2026-06 | $1.58 | +12.1% |
| 2026-07 | $1.01 | -36.1% |
| 2026-08 | $0.86 | -15.1% |
| 2026-09 | $1.08 | +25.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.08 |
| Market Cap | $28M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.18 |
| EV / EBITDA | -7.04 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.17 |
| Current Ratio | 0.07 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.61 |